Bridge Biotherapeutics Inc.

Plus: A pair of ADC deals between Merck-Kelun, Adcendo-Multitude

Alnylam announced a three-month data delay and endpoint shift in Phase III HELIOS-B

The Korean biotech’s collaboration with Vividion co-founders at Scripps will explore reactive chemistries beyond cysteine

BioCentury’s roundup of translational news

Plus: Neuroblastoma approval for BeiGene, priority review for Agios’ mitapivat, Arctic Vision, Vectura, AnaptysBio and more

ASCO21 abstracts highlight opportunities for new EGFR-targeting agents and combos to fill holes left by TKIs

James Lee-led biotech has honed its focus and begun seeking deals as far off as Europe

Eric Koo will become CEO of Overland ADCT BioPharma (CY) Ltd., the joint venture between Overland Pharmaceuticals and ADC Therapeutics S.A. (NYSE:ADCT) that launched in December. The JV is

A Cherry in MorphoSys’ hunt for new techMorphoSys AG (Xetra:MOR; NASDAQ:MOR) entered an exclusive licensing agreement with University Hospital Würzburg spinout Cherry Biolabs GmbH for